Alyssa R. Summers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alyssa R. Summers has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Jonathan F. Kaiser
Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
1 shared publication- Kristy R. Stengel
Albert Einstein College of Medicine 1 Department of Cell Biology Bronx, New York
1 shared publication Laura E. Gordy
Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
1 shared publicationNicholas J. Klus
Department of Biology, The University of the South: Sewanee, Sewanee, Tennessee, USA
1 shared publication- Scott W. Hiebert
Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA; Vanderbilt-Ingram Cancer Center, Nashville, TN 37027, USA
1 shared publication - Sebastian Joyce
Tennessee Valley Healthcare System
1 shared publication
Latest Publications
- Open Access
- 1 November 2015
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 35 (22) , 3854-3865
Histone Deacetylase 3 Is Required for Efficient T Cell Development
Hdac3 is a key target for Hdac inhibitors that are efficacious in cutaneous T cell lymphoma. Moreover, the regulation of chromatin structure is critical as thymocytes transition from an immature cell with open chromatin to a mature T cell with tightly condensed chromatin. To define the phenotypes controlled by Hdac3 during T cell development, we conditionally deleted Hdac3 using the Lck-Cre transgene. This strategy inactivated Hdac3 in the double negative stages of thymocyte development and caused a significant impairment at the CD8 immature single positive stage (ISP) and CD4/CD8 double positive stage with few mature CD4+ or CD8+ single positive cells being produced. When the Hdac3-/- mice were crossed with Bcl-xL, Bcl2, or TCRβ-expressing transgenic mice, a modest level of complementation was found. However, when the null mice were crossed with mice expressing a fully rearranged TCRαβ transgene, normal levels of CD4 single positive cells were produced. Thus, Hdac3 was required for efficient transit from double negative stage 4 through positive selection.
- 1 November 2015
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 35 (22) , 3854-3865
Open AccessHistone Deacetylase 3 Is Required for Efficient T Cell Development
Hdac3 is a key target for Hdac inhibitors that are efficacious in cutaneous T cell lymphoma. Moreover, the regulation of chromatin structure is critical as thymocytes transition from an immature cell with open chromatin to a mature T cell with tightly condensed chromatin. To define the phenotypes controlled by Hdac3 during T cell development, we conditionally deleted Hdac3 using the Lck-Cre transgene. This strategy inactivated Hdac3 in the double negative stages of thymocyte development and caused a significant impairment at the CD8 immature single positive stage (ISP) and CD4/CD8 double positive stage with few mature CD4+ or CD8+ single positive cells being produced. When the Hdac3-/- mice were crossed with Bcl-xL, Bcl2, or TCRβ-expressing transgenic mice, a modest level of complementation was found. However, when the null mice were crossed with mice expressing a fully rearranged TCRαβ transgene, normal levels of CD4 single positive cells were produced. Thus, Hdac3 was required for efficient transit from double negative stage 4 through positive selection.